Lori J. Wirth

An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.

M. Kreissl, M. Schlumberger, P. Schőffski, 2012 .

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

M. Kreissl, M. Schlumberger, M. Brose, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.

R. Tishler, D. Shin, L. Raez, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Thyroid carcinoma, version 2.2014.

J. Shah, A. Iagaru, C. Hoh, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Thyroid carcinoma.

J. Olson, R. Kloos, D. Byrd, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.